The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The approval of Isa-VRd in myeloma and comparing Isa-VRd to Dara-VRd
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses recent advancements in multiple myeloma (MM) treatment, noting the approval of several immunotherapies in the US within the last two years. The effectiveness and durability of novel antibody treatments, regardless of transplant eligibility, suggest that these therapies may shift current treatment paradigms. Prof. Landgren also mentions the recent approval of isatuximab combined with standard-of-care bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in transplant-ineligible, newly diagnosed patients and comments on whether Isa-VRd or daratumumab plus VRd (Dara-VRd) will be a better treatment strategy in this population. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
